Document Detail

Arthrotec: a therapeutic option in the management of arthritis.
MedLine Citation:
PMID:  7821336     Owner:  NLM     Status:  MEDLINE    
Arthrotec (Searle) is a new concept in NSAID therapy that provides powerful anti-inflammatory efficacy with enhanced upper GI safety. Arthrotec comprises an enteric-coated core of diclofenac sodium (50 mg) surrounded by a mantle of misoprostol (200 mcg). Two multicentre trials evaluated the efficacy of Arthrotec in rheumatoid arthritis (RA) and osteoarthritis (OA) patients who were randomised to receive either Arthrotec or diclofenac. The results of all arthritis assessments showed Arthrotec to be as effective as diclofenac in treating the signs and symptoms of RA and OA. Two endoscopic studies compared the antiarthritic efficacy and gastroduodenal safety of Arthrotec and diclofenac. In a 12-week study of RA patients, the antiarthritic efficacy of Arthrotec was equivalent to diclofenac; in addition, 60% fewer patients taking Arthrotec experienced ulcers than did those taking diclofenac (4.4% Arthrotec vs 11.1% diclofenac: P = 0.034). In a 4-week study of OA patients, Arthrotec's efficacy was equivalent to that of diclofenac and the Arthrotec group developed no ulcers, while 3.6% of the diclofenac group had ulcers (P = 0.015). In a trial conducted to compare the efficacy and upper gastroduodenal safety of Arthrotec with those of piroxicam and naproxen, patients with OA received either Arthrotec BID piroxicam 10 mg BID, or naproxen 375 BID for 4 weeks. Arthritis assessments showed Arthrotec to be at least as effective as piroxicam and naproxen in treating OA. Post-treatment endoscopy data indicated that gastroduodenal ulcers developed in 1.5% of patients receiving Arthrotec, 10.3% of patients receiving piroxicam, and 8.6% patients in the naproxen group.(ABSTRACT TRUNCATED AT 250 WORDS)
G S Geis
Related Documents :
9776116 - Comparative study of tetranectin levels in serum and synovial fluid of patients with rh...
19772796 - Poor to modest agreement between rheumatoid arthritis response measures in clinical pra...
10555886 - Tacrolimus (fk506) in the treatment of severe, refractory rheumatoid arthritis: initial...
24615466 - The effect of amyloid pathology and glucose metabolism on cortical volume loss over tim...
2458376 - Protein synthesis and quantitative morphology in thyroid tissue from hyperthyroid patie...
3345876 - Clinicopathological features of nonsteroidal antiinflammatory drug-induced small intest...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  European journal of rheumatology and inflammation     Volume:  13     ISSN:  0140-1610     ISO Abbreviation:  Eur J Rheumatol Inflamm     Publication Date:  1993  
Date Detail:
Created Date:  1995-02-16     Completed Date:  1995-02-16     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7805765     Medline TA:  Eur J Rheumatol Inflamm     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  25-32     Citation Subset:  IM    
Searle, Skokie, IL 60077.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anti-Inflammatory Agents, Non-Steroidal / standards,  therapeutic use*
Arthritis / drug therapy*
Clinical Trials as Topic
Diclofenac / standards,  therapeutic use*
Double-Blind Method
Drug Combinations
Misoprostol / standards,  therapeutic use*
Multicenter Studies as Topic
Randomized Controlled Trials as Topic
Reg. No./Substance:
0/Anti-Inflammatory Agents, Non-Steroidal; 0/Arthrotec; 0/Drug Combinations; 15307-86-5/Diclofenac; 59122-46-2/Misoprostol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Anti-inflammatories and gastroduodenal damage: therapeutic options.
Next Document:  The economic consequences of NSAID-induced gastrointestinal damage.